| SNV’s; Indels | AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO |
| CNV’s | AKT1, ALK, AR, BRAF, CCND1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA |
| Fusions | ABL1, AKT3, ALK, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1 |
All types of solid tumors showing the presence of mutation and copy number variation, in the genes present in oncomine focus assay. Hence, this assay best suited to identify druggable mutation, driver mutation or CNV changes and prognostic bio-markers.
Analyzed using: cbioportal.org.
Multiple tumors such as Bone sarcoma, breast cancer, CRC, cholangiocarcinoma, gastric cancer, Head and neck cancer, melanoma, lung cancer, prostate cancer, salivary gland carcinoma, thyroid cancer, uterine sarcoma are showing fusion drivers in >2% of the cases, that can be detected by Oncomine focus assay.
Analyzed using: cbioportal.org.
| List of FDA approved drugs covered | ||
|---|---|---|
| Biomarker | Drugs | Disease |
| BRAF V600E; BRAF V600K | Vemurafenib, Cobimetinib, Dabrafenib, Trametinib, Atezolizumab, Encorafenib | Melanoma, NSCLC, CRC |
| ALK Fusion, EML4-ALK | Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib | NSCLC |
| c-KIT | Imatinib, Sunitinib, Regorafenib, Ripertinib | GIST |
| EGFR | Cetuximab, Mobocertinib, Afatinib, Gefitinib, Amivantamb, Osimertinib, Erlotinib | Lung cancer |
| EGFR | Panitumumab, Dacomitinib | CRC |
| ERBB2 | Fam-trastuzumab Deruxtecan-nxki | NSCLC |
| ERBB2/HER2 amplification | Trastuzumab, Pertuzumab, Ado-trastuzumab Emtansine | Breast cancer, Gastric cancer |
| FGFR2-Fusions | Pemigatinib, Infigratinib | Cholangiocarcinoma |
| FGFR3 mutation/Fusion | Erdafitinib | Urothelial Cancer |
| KRAS | Cetuximab, Panitumumab, Sotorasib | CRC, NSCLC |
| NRAS | Panitumumab | CRC |
| MET, exon skipping | Capmatinib | NSCLC |
| NTRK1, NTRK2, NTRK3-fusions | Larotrectinib, Entrectinib | Pan solid tumors |
| PIK3CA | Olaparib, Alpelisib | Breast cancer, Pan solid tumors |
| RET-Fusions | Pralsetinib, Selpercatinib | NSCLC |
| RET-Fusions/mutation | Selpercatinib | Thyroid cancer |
| Ros1-fusions | Entrectinib, Crizotinib | NSCLC |
